Stryker Corporation (SYK) is generating increased interest from various investment groups including
Oregon Public Employees Retirement Fund, Will, and
DSM Capital Partners LLC. Despite
Parnassus Investments LLC and
Keslar Norman & Wride LLC reducing their stakes, the company's shares remain attractive to others. SYK's longstanding investors have enjoyed a
54% return in the last five years. We expect the upcoming financial reports' results for Q4 and the year 2025, to influence the stock’s trajectory. Analysts have given SYK a consensus rating of
Moderate Buy. In addition, leadership changes and a potential outperform upgrade from
Raymond James may prompt further investment. Stryker recently opened a
140,000-Sq-Ft R&D Hub in India focusing on AI and robotics. Rebalancing of portfolios has led
Ethic Inc,
Banque Pictet & Cie SA, and
Confluence Investment Management LLC to sell off some SYK shares. Dividend increase and executive team shifts are among the recent developments affecting SYK's investment narrative. Despite some fluctuations in the stock market, SYK shares remain popular among corporations and individual investors. SYK anticipates strong organic growth and strategic changes, with a potential
20.86% upside in the medical devices sector.
Stryker Corporation SYK News Analytics from Tue, 15 Apr 2025 07:00:00 GMT to Sat, 10 Jan 2026 13:04:21 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor -3
